B型肝炎治療市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、治療別、流通チャネル別、地域別、競合別、2020～2030年

B型肝炎治療の世界市場規模は、2024年に48億9,000万米ドルとなり、2030年には62億1,000万米ドルに達し、予測期間中のCAGRは4.03%で成長すると予測されています。

この成長の主因は、世界のB型肝炎感染者の増加です。B型慢性肝炎は、肝硬変や肝細胞がんなどの重篤な合併症の原因となっており、公衆衛生上の重要な課題となっています。B型肝炎の負担が増加していることから、ヘルスケア機関や政府は予防接種プログラムや啓発キャンペーンを広く実施するようになり、早期発見や治療率が向上しています。診断ツールや抗ウイルス薬、インターフェロン療法などの治療オプションへのアクセスの拡大も、市場成長にプラスの影響を与えています。B型慢性肝炎を管理するための一次治療としてヌクレオシドアナログの採用が増加していることも、市場拡大をさらに加速しています。製薬企業は、安全性プロファイルを強化した、より効果的で的を絞った治療法を導入するため、研究開発に多額の投資を行っています。薬剤開発と治療アプローチのイントロダクションの進歩は市場に利益をもたらしており、併用療法の導入はウイルス複製を減少させ、疾患の進行を予防する上で効果的であることが証明されつつあります。個別化医療へのシフトが進むことで、オーダーメイドの治療計画を立てる機会が生まれ、患者の転帰が向上しています。さらに、新興国におけるヘルスケア・インフラの拡充は、B型肝炎治療への患者のアクセスを増加させ、市場の成長を支えています。遠隔医療や遠隔モニタリングなどのデジタルヘルスソリューションの統合は、特に医療アクセスが限られている地域において、治療のアドヒアランスと疾病管理を向上させています。RNAベースの治療薬や免疫調整薬など、機能的な治療薬や革新的な治療法を開発するための継続的な取り組みが、市場の今後の方向性に影響を与えると予想されます。

主な市場促進要因

主な市場課題：

主要市場動向：

目次

1.製品概要

• 市場の定義
• 市場の範囲
  • 対象市場
  • 調査対象年
  • 主要市場セグメンテーション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のB型肝炎治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（急性、慢性）
  • 治療別（免疫調節薬、抗ウイルス薬、ワクチン、手術）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米のB型肝炎治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のB型肝炎治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のB型肝炎治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のB型肝炎治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのB型肝炎治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Bristol-Myers Squibb
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Accord Healthcare Inc.
• Apotex Corp.
• Arbutus Biopharma Corp
• Arrowhead Pharma Inc
• Aurobindo Pharma Limited
• Lupin Pharmaceuticals Inc.
• Merck & Co. Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Hepatitis B Treatment Market was valued at USD 4.89 billion in 2024 and is projected to reach USD 6.21 billion by 2030, growing at a CAGR of 4.03% during the forecast period. This growth is primarily driven by the increasing prevalence of hepatitis B infections worldwide. Chronic hepatitis B continues to be a significant public health challenge, contributing to severe complications such as liver cirrhosis and hepatocellular carcinoma. The rising burden of hepatitis B has prompted both healthcare organizations and governments to implement widespread vaccination programs and awareness campaigns, which have improved early detection and treatment rates. Expanded access to diagnostic tools and treatment options, including antiviral medications and interferon therapies, is also positively influencing market growth. The increasing adoption of nucleoside analogs as a primary treatment for managing chronic hepatitis B is further accelerating market expansion. Pharmaceutical companies are heavily investing in research and development to introduce more effective and targeted therapies with enhanced safety profiles. Advancements in drug development and treatment approaches are benefiting the market, and the introduction of combination therapies is proving effective in reducing viral replication and preventing disease progression. The growing shift toward personalized medicine is creating opportunities for tailored treatment plans, enhancing patient outcomes. Additionally, the expansion of healthcare infrastructure in emerging economies is supporting market growth by increasing patient access to hepatitis B treatments. The integration of digital health solutions, such as telemedicine and remote monitoring, is improving treatment adherence and disease management, particularly in regions with limited healthcare access. Ongoing efforts to develop functional cures and innovative treatments, such as RNA-based therapies and immune modulators, are expected to influence the market's future direction.

Key Market Drivers:

Rising Hepatitis B Prevalence: Hepatitis B, a viral infection that primarily affects the liver, remains a significant global health concern. As of 2022, the World Health Organization (WHO) estimated that 254 million people were living with chronic hepatitis B, with 1.2 million new infections each year. The prevalence of hepatitis B varies widely by region. In the WHO Western Pacific Region, the prevalence among the general population was 5.92% in 2019, affecting 97 million people. In comparison, the WHO African Region had a prevalence rate of 3.5%, equating to 65 million individuals living with chronic hepatitis B. Mother-to-child transmission during childbirth or breastfeeding is a key mode of transmission, particularly in high-prevalence regions. Inadequate infection control practices and the reuse of syringes and needles in healthcare settings contribute to the spread of hepatitis B. Additionally, unprotected sexual activity and sharing injection drug paraphernalia increase the risk of transmission. The growing number of individuals diagnosed with hepatitis B significantly expands the patient pool requiring treatment, which drives the demand for antiviral drugs, therapies, and vaccines. Chronic hepatitis B often necessitates long-term treatment, fostering a sustained market for pharmaceutical companies producing hepatitis B medications. Many governments have launched public awareness campaigns to educate people about hepatitis B, encouraging testing and treatment, which further stimulates market demand. Vaccination programs, particularly for infants, have been introduced in many regions to reduce transmission rates. However, despite these efforts, a substantial number of individuals remain infected and require ongoing treatment.

Key Market Challenges:

High Treatment Costs: A major challenge hindering the growth of the Global Hepatitis B Treatment Market is the high cost of treatment. This presents a significant barrier to access, particularly in low- and middle-income countries. Hepatitis B treatment often involves long-term use of antiviral drugs, which can be costly. Over several years, the cumulative cost of treatment can become a financial burden for patients. In some regions, health insurance coverage may not include hepatitis B treatment, leaving patients responsible for the full cost, which further limits treatment access. These high treatment costs contribute to healthcare disparities, as individuals with limited financial resources may struggle to afford hepatitis B medications, leading to delayed or insufficient treatment and hindering market growth.

Key Market Trends:

Increased Focus on Combination Therapies: A prominent trend in the Global Hepatitis B Treatment Market is the increasing emphasis on combination therapies. Chronic hepatitis B requires long-term management, and treatment strategies are evolving beyond monotherapies. Combining multiple therapeutic agents, such as antiviral drugs and immune-modulating therapies, has shown promise in improving treatment outcomes and reducing the risk of resistance. Combination therapies target various stages of the viral replication cycle, providing a more comprehensive approach to managing the infection. The shift toward combination treatments is driven by the need for more effective and sustainable solutions to combat hepatitis B. The limitations of monotherapy, including the risk of viral resistance and the potential for inadequate viral suppression, have led to the exploration of combination regimens. For example, combining nucleos(t)ide analogues (NUCs) with immune modulators or other antiviral agents can suppress viral replication more effectively and improve patient outcomes. These combinations help lower the likelihood of breakthrough infections and reduce the frequency of dose adjustments. The rising adoption of combination therapies aligns with advancements in personalized medicine, where treatment can be tailored based on factors such as viral genotype, disease stage, and patient response. As a result, pharmaceutical companies are intensifying research into combination therapies, with several promising treatments in clinical trials. This trend is expected to continue, leading to the development of more effective and well-tolerated therapeutic options for hepatitis B.

Key Market Players:

• Bristol-Myers Squibb
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Accord Healthcare Inc.
• Apotex Corp.
• Arbutus Biopharma Corp.
• Arrowhead Pharma Inc.
• Aurobindo Pharma Limited
• Lupin Pharmaceuticals Inc.
• Merck & Co. Inc.

Report Scope: This report segments the Global Hepatitis B Treatment Market as follows, with detailed industry trends:

By Type:

• Acute
• Chronic

By Treatment:

• Immune Modulator Drugs
• Antiviral Drugs
• Vaccines
• Surgery

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape: Company profiles and detailed analysis of key players in the Global Hepatitis B Treatment Market.

Available Customizations: This report offers customizable options tailored to specific business needs, including:

• Additional company analysis and profiling (up to five companies).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Hepatitis B Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Acute, Chronic)
  • 5.2.2. By Treatment (Immune Modulator Drugs, Antiviral Drugs, Vaccines, Surgery)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Hepatitis B Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hepatitis B Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Hepatitis B Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Hepatitis B Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Distribution Channel

7. Europe Hepatitis B Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Hepatitis B Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Hepatitis B Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Hepatitis B Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Hepatitis B Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Hepatitis B Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Hepatitis B Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Hepatitis B Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Hepatitis B Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Hepatitis B Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Hepatitis B Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Hepatitis B Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Distribution Channel

9. South America Hepatitis B Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Hepatitis B Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Hepatitis B Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Hepatitis B Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Hepatitis B Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1.By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3.By Distribution Channel
  • 10.2.4.By Country
• 10.3. MEA: Country Analysis
  • 10.3.1.South Africa Hepatitis B Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2.Saudi Arabia Hepatitis B Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3.UAE Hepatitis B Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Bristol-Myers Squibb
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products& Services
  • 14.1.4. Financials(As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Gilead Sciences, Inc.
• 14.3. GlaxoSmithKline PLC
• 14.4. Accord Healthcare Inc.
• 14.5. Apotex Corp.
• 14.6. Arbutus Biopharma Corp
• 14.7. Arrowhead Pharma Inc
• 14.8. Aurobindo Pharma Limited
• 14.9. Lupin Pharmaceuticals Inc.
• 14.10. Merck & Co. Inc.

15. Strategic Recommendations

16. About Us & Disclaimer